Novel targets in the management of pneumonia

Marcos I. Restrepo, Luis A. Díaz, Eric M. Mortensen, Antonio Anzueto

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Community-acquired pneumonia (CAP) is the leading cause of death from infectious diseases in the US. It accounts each year for 500,000 hospitalizations and 45,000 deaths and represents one of the most common causes of intensive care unit (ICU) admission. The mortality rate due to severe CAP has shown little improvement in the past three decades, remaining between 21% and 58% in patients admitted to the intensive care unit. Antimicrobial agents are the cornerstone of therapy against CAP, but there are some novel antibiotic and nonantibiotic therapies that have been recently tested that may potentially impact outcomes of patients with severe CAP. We will review the most recent data regarding novel therapies in patients with the highest risk of death such as those with severe CAP.

Original languageEnglish (US)
Pages (from-to)387-400
Number of pages14
JournalTherapeutic Advances in Respiratory Disease
Volume2
Issue number6
DOIs
StatePublished - 2008

Fingerprint

Pneumonia
Intensive Care Units
Anti-Infective Agents
Communicable Diseases
Cause of Death
Hospitalization
Therapeutics
Anti-Bacterial Agents
Mortality

Keywords

  • Community-acquired infections
  • Intensive care unit
  • Pneumonia
  • Therapeutics

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Pharmacology (medical)

Cite this

Novel targets in the management of pneumonia. / Restrepo, Marcos I.; Díaz, Luis A.; Mortensen, Eric M.; Anzueto, Antonio.

In: Therapeutic Advances in Respiratory Disease, Vol. 2, No. 6, 2008, p. 387-400.

Research output: Contribution to journalArticle

Restrepo, Marcos I. ; Díaz, Luis A. ; Mortensen, Eric M. ; Anzueto, Antonio. / Novel targets in the management of pneumonia. In: Therapeutic Advances in Respiratory Disease. 2008 ; Vol. 2, No. 6. pp. 387-400.
@article{62c107f3409147e880da3160bdb05703,
title = "Novel targets in the management of pneumonia",
abstract = "Community-acquired pneumonia (CAP) is the leading cause of death from infectious diseases in the US. It accounts each year for 500,000 hospitalizations and 45,000 deaths and represents one of the most common causes of intensive care unit (ICU) admission. The mortality rate due to severe CAP has shown little improvement in the past three decades, remaining between 21{\%} and 58{\%} in patients admitted to the intensive care unit. Antimicrobial agents are the cornerstone of therapy against CAP, but there are some novel antibiotic and nonantibiotic therapies that have been recently tested that may potentially impact outcomes of patients with severe CAP. We will review the most recent data regarding novel therapies in patients with the highest risk of death such as those with severe CAP.",
keywords = "Community-acquired infections, Intensive care unit, Pneumonia, Therapeutics",
author = "Restrepo, {Marcos I.} and D{\'i}az, {Luis A.} and Mortensen, {Eric M.} and Antonio Anzueto",
year = "2008",
doi = "10.1177/1753465808098694",
language = "English (US)",
volume = "2",
pages = "387--400",
journal = "Therapeutic Advances in Respiratory Disease",
issn = "1753-4658",
publisher = "SAGE Publications Ltd",
number = "6",

}

TY - JOUR

T1 - Novel targets in the management of pneumonia

AU - Restrepo, Marcos I.

AU - Díaz, Luis A.

AU - Mortensen, Eric M.

AU - Anzueto, Antonio

PY - 2008

Y1 - 2008

N2 - Community-acquired pneumonia (CAP) is the leading cause of death from infectious diseases in the US. It accounts each year for 500,000 hospitalizations and 45,000 deaths and represents one of the most common causes of intensive care unit (ICU) admission. The mortality rate due to severe CAP has shown little improvement in the past three decades, remaining between 21% and 58% in patients admitted to the intensive care unit. Antimicrobial agents are the cornerstone of therapy against CAP, but there are some novel antibiotic and nonantibiotic therapies that have been recently tested that may potentially impact outcomes of patients with severe CAP. We will review the most recent data regarding novel therapies in patients with the highest risk of death such as those with severe CAP.

AB - Community-acquired pneumonia (CAP) is the leading cause of death from infectious diseases in the US. It accounts each year for 500,000 hospitalizations and 45,000 deaths and represents one of the most common causes of intensive care unit (ICU) admission. The mortality rate due to severe CAP has shown little improvement in the past three decades, remaining between 21% and 58% in patients admitted to the intensive care unit. Antimicrobial agents are the cornerstone of therapy against CAP, but there are some novel antibiotic and nonantibiotic therapies that have been recently tested that may potentially impact outcomes of patients with severe CAP. We will review the most recent data regarding novel therapies in patients with the highest risk of death such as those with severe CAP.

KW - Community-acquired infections

KW - Intensive care unit

KW - Pneumonia

KW - Therapeutics

UR - http://www.scopus.com/inward/record.url?scp=68749094400&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68749094400&partnerID=8YFLogxK

U2 - 10.1177/1753465808098694

DO - 10.1177/1753465808098694

M3 - Article

C2 - 19124384

AN - SCOPUS:68749094400

VL - 2

SP - 387

EP - 400

JO - Therapeutic Advances in Respiratory Disease

JF - Therapeutic Advances in Respiratory Disease

SN - 1753-4658

IS - 6

ER -